Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
A Phase 3, Open-label, Multi-center, Single-arm Study to Assess Contraceptive Efficacy and Safety of the Nomegestrol Acetate + 17β-estradiol Combined Oral Contraceptive (OG-8175A) in Premenopausal Females Aged 14 to 35 Years (Inclusive)
Sponsor: Iqvia Pty Ltd
Terminated
Sponsor decision to stop the study early and complete all required study close-out activities. This decision was made for business reasons unrelated to safety. None of the pre-specified efficacy endpoints were analyzed.
Other terminated trials from Iqvia Pty Ltd
- Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome · Phase PHASE2 · Aug 2024
- Post-traumatic Stress Disorder (PTSD) · Phase PHASE1 · Aug 2023
- Postpartum Depression · Phase NA · May 2023
- Cancer - Solid Tumours · Phase PHASE1 · Dec 2020
More terminations from Iqvia Pty Ltd
Other Contraception trials with similar outcome
A PHASE3 clinical study on Contraception, this trial is terminated or withdrawn. The trial is conducted by Iqvia Pty Ltd and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Dec 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Jan 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Nov 2022 — Jan 2024 [monthly]
Recruiting PHASE3
-
Apr 2022 — Nov 2022 [monthly]
Recruiting PHASE3
First recorded
Feb 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Iqvia Pty Ltd
- Organon and Co
For direct contact, visit the study record on ClinicalTrials.gov .